Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-CEACAM1 Antibody-PE (7F98) is a PE-conjugated Mouse antibody targeting CEACAM1. Anti-CEACAM1 Antibody-PE (7F98) can be used in FCM.
Description | Anti-CEACAM1 Antibody-PE (7F98) is a PE-conjugated Mouse antibody targeting CEACAM1. Anti-CEACAM1 Antibody-PE (7F98) can be used in FCM. |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 7F98 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human CEACAM1(CD66a) expression on HT29 cells. Cells were stained with PE-conjugated anti-Human CEACAM1(CD66a). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 5 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CEACAM1 / CD66a (rh CEACAM1 / CD66a; TMPY-00717; NP_001020083.1; Met1-Gly428) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | The carcinoembryonic-antigen-related cell-adhesion molecule (CEACAM) family of proteins has been implicated in various intercellular-adhesion and intracellular-signalling-mediated effects that govern the growth and differentiation of normal and cancerous cells. CEACAM1, also known as biliary glycoprotein I (BGP I) and CD66a, is a member of the carcinoembryonic antigen (CEA) gene family which belongs to the immunoglobulin superfamily. The highly glycosylated CEACAM1 contains one N-terminal V-type Ig-like domain and three C2-type Ig-like domains within its ECD, and one ITIM motif and a calmodulin binding site in the cytoplasmic region. CEACAM1 is a surface glycoprotein expressed on various blood cells, epithelial cells, and vascular cells. It was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | PE |
Others Formats | Unconjugated/APC/FITC |
Antibody Types Available | 4 |
Immunogen | Recombinant Human CEACAM1 / CD66a protein (TMPY-00717) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.